(:PTE)
Business Focus: N/A
Dec 27, 2022 07:30 am ET
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company
SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock uni
Nov 10, 2022 03:30 pm ET
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022.
Nov 09, 2022 07:00 am ET
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of cont
Sep 13, 2022 08:30 am ET
PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022
SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City at 11:00 am, ET, on September 14, 2022.
Sep 08, 2022 08:30 am ET
PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors
SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.
Aug 11, 2022 04:05 pm ET
PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET
Aug 01, 2022 08:00 am ET
PolarityTE to Report Q2 2022 Financial Results on August 11, 2022
SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.
Jun 06, 2022 08:00 am ET
PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY, June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, PolarityTE also agreed to issue and sell to the investo
May 23, 2022 08:00 am ET
PolarityTE to Attend H.C. Wainwright Global Investment Conference
SALT LAKE CITY, May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.
May 16, 2022 04:15 pm ET
PolarityTE to Effectuate 1-for-25 Reverse Stock Split
SALT LAKE CITY, May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022. As of that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. A new CUSIP number has been assigned to the Company's common stock as a res
May 16, 2022 07:30 am ET
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET
May 13, 2022 10:08 am ET
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glauco
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PolarityTE, Inc. (NASDAQ: PTE) Veru Inc. (NASDAQ:...
May 13, 2022 08:00 am ET
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
SALT LAKE CITY, May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company's open IND.
May 11, 2022 04:52 pm ET
Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQCM: SAVA), The Honest Company, Inc. (NASDAQGS: HNST), PolarityTE, Inc. (NASDAQCM: PTE), Selectquote, Inc. (NYSE: SLQT) SAVA,
Cassava Sciences, Inc. (NASDAQCM: SAVA) Lifshitz Law PLLC announces that a class action complaint was filed against Cassava alleging Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of...
May 06, 2022 08:00 am ET
PolarityTE to Report Q1 2021 Financial Results on May 16, 2022
SALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.
May 03, 2022 08:00 am ET
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
SALT LAKE CITY, May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE," or "COVER DFUs."
Apr 13, 2022 11:01 am ET
Thinking about buying stock in Agile Therapeutics, Polarityte, Bed Bath & Beyond, Tellurian, or Phio Pharmaceuticals?
NEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, PTE, BBBY, TELL, and PHIO.
Apr 13, 2022 10:00 am ET
Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Healt
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N.V....
Apr 12, 2022 10:45 am ET
Thinking about buying stock in Polarityte, RLX Technology, Bitnile, Aterian, or Cyclacel Pharmaceuticals?
NEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, RLX, NILE, ATER, and CYCC.
Apr 12, 2022 08:58 am ET
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: PolarityTE, Inc. (NASDAQ: PTE) Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Biodesix, Inc. (NASDAQ:...
Mar 30, 2022 07:30 am ET
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET
Mar 16, 2022 04:37 pm ET
PolarityTE Announces Closing of $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock. Each share of Series A and Series B preferred sto
Mar 16, 2022 08:00 am ET
PolarityTE Announces $5.0 Million Registered Direct Offering
SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock and 2,000.00029 shares of Series B convertible preferred stock and warrants to purchase up to an aggregate of 16,393,445 shares of common stock. Each share of Series A and Series B preferred stock has a state
Mar 10, 2022 07:00 am ET
PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022
SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2022, at approximately 7:30 a.m. Eastern Time.
Feb 17, 2022 07:00 am ET
PolarityTE Announces Allowance of Fourth U.S. Patent
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021. This is the Company's fourth patent allowance in the United States. The newly allowed claims are for compositions that relate to the Company's minimally polarized functional unit (MPFU) technology in combination with a cryoprotectant.
Jan 18, 2022 08:31 am ET
Thinking about buying stock in Polarityte, Opko Health, Ion Geophysical, National CineMedia, or Playtika?
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, OPK, IO, NCMI, and PLTK.
Jan 18, 2022 07:00 am ET
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified. The approval enables PolarityTE to commence the first of two expected pivotal studies needed to support a biologics licens
Jan 03, 2022 07:30 am ET
Thinking about buying stock in Siyata Mobile, Nine Energy Service, BlueCity, Polarityte, or Frontline?
NEW YORK, Jan. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYTA, NINE, BLCT, PTE, and FRO.
Dec 23, 2021 12:58 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of AppHarvest, Inc. (NASDAQGS: APPH), The Boston Beer Company, Inc. (NYSE: SAM), The Honest Company, Inc. (NASDAQGS: HNST), and PolarityTE, Inc. (NASDA
AppHarvest, Inc. (NASDAQGS: APPH) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against APPH alleging Defendants failed to disclose to investors: (1) that APPH lacked sufficient training for its recently expanded...
Dec 20, 2021 07:00 am ET
PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administration's (FDA) clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers. As previously disclosed, the primary hold issues are certain Chemistry, Manufacturing, and Control (CMC) items, including the assay to demonstrate the potency of SkinTE.
Dec 01, 2021 10:00 pm ET
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf of long-term stockholders following a class action complaint that was filed against PolarityTE on September 24, 2021. Our investigation concerns whether the board of directors of PolarityTE have breached their fiduciary duties to the company.
Nov 23, 2021 11:00 am ET
Last Few Hours to Actively Participate in PolarityTE, Inc. Class Action: Bronstein, Gewirtz & Grossman, LLC
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Nov 22, 2021 11:00 pm ET
POLARITYTE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District...
Nov 22, 2021 10:37 am ET
PTE FINAL DEADLINE TOMORROW: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Ac
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead...
Nov 19, 2021 07:20 pm ET
Nov 18, 2021 10:00 am ET
APPH, PTE & HYZN – Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz...
Nov 16, 2021 09:00 pm ET
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District...
Nov 15, 2021 08:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline - PTE
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of Utah, and docketed under 21-cv-00561, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defe
Nov 14, 2021 11:58 am ET
ROSEN, A TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 23 Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead...
Nov 11, 2021 10:48 am ET
PolarityTE, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of U
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period").
Nov 10, 2021 09:00 pm ET
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the “Class Period”). Investors have until November 23, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Nov 10, 2021 06:00 am ET
PolarityTE Reports Third Quarter Financial Results and Provides Business Update
SALT LAKE CITY, Nov. 10, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the three and nine-month periods ended September 30, 2021.
Nov 09, 2021 04:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – PTE
Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District...
Nov 08, 2021 10:00 am ET
APPH, PTE & HYZN, HYZNW, DCRB, DCRBW, DCRBU - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 05, 2021 08:12 pm ET
Nov 04, 2021 03:05 am ET
POLARITYTE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United StatesDistrict Court for the District of U
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period").
Nov 03, 2021 11:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline - PTE
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of Utah, and docketed under 21-cv-00561, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defen
Nov 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PolarityTE, Hyzon Motors, Nano-X, and Eargo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PolarityTE, Inc. (NASDAQ: PTE), Hyzon Motors, Inc. (NASDAQ: HYZN), Nano-X...
Nov 02, 2021 04:37 pm ET
ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead...
Nov 01, 2021 02:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – PTE
Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of...
Nov 01, 2021 10:52 am ET
UPDATE -- APPH, PTE & HYZN, HYZNW, DCRB, DCRBW, DCRBU - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Actions and Lead Plaintiff Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 28, 2021 08:36 am ET
PolarityTE, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period").
Oct 28, 2021 08:00 am ET
PolarityTE to Report Third Quarter Financial Results on November 10, 2021
SALT LAKE CITY, Oct. 28, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended September 30, 2021 by press release on Wednesday, November 10, 2021 at approximately 7:00 a.m. Eastern Time.
Oct 27, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PolarityTE, Hyzon Motors, Nano-X, and Eargo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PolarityTE, Inc. (NASDAQ: PTE), Hyzon Motors, Inc. (NASDAQ: HYZN), Nano-X...
Oct 27, 2021 05:52 pm ET
ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors With Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Action – PTE
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead plaintiff...
Oct 25, 2021 11:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline - PTE
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of Utah, and docketed under 21-cv-00561, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Def
Oct 25, 2021 10:00 am ET
APPH, PTE & HYZN, HYZNW, DCRC, DCRCW, DCRCU - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Actions and Lead Plaintiff Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 24, 2021 02:30 pm ET
Oct 20, 2021 06:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – PTE
Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of...
Oct 19, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PolarityTE, Hyzon Motors, Nano-X, and Eargo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PolarityTE, Inc. (NASDAQ: PTE), Hyzon Motors, Inc. (NASDAQ: HYZN), Nano-X...
Oct 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PolarityTE, Nano-X, and Eargo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PolarityTE, Inc. (NASDAQ: PTE), Nano-X Imaging Ltd. (NASDAQ: NNOX), and Eargo,...
Oct 13, 2021 06:45 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead...
Oct 11, 2021 04:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – PTE
Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of...
Oct 09, 2021 11:30 am ET
ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
WHY: New York, N.Y., October 9, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead plaintiff deadline.
Oct 07, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Koninklije Philips, PayPal, Boston Beer, and PolarityTE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Koninklijke Philips N.V. (NYSE: PHG), PayPal Holdings, Inc. (NASDAQ: PYPL), The...
Oct 07, 2021 07:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline - PTE
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of Utah, and docketed under 21-cv-00561, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defen
Oct 07, 2021 05:45 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”), of the important November 23, 2021 lead...
Oct 07, 2021 11:00 am ET
PTE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies PolarityTE, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Oct 07, 2021 08:00 am ET
PolarityTE Provides Update on Investigational New Drug Application
SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers submitted to the Food and Drug Administration (FDA) in July 2021.
Oct 05, 2021 09:45 pm ET
Oct 05, 2021 10:00 am ET
PTE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies PolarityTE, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers, on behalf of shareholders...
Oct 03, 2021 08:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – PTE
Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of...
Oct 02, 2021 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Koninklije Philips, PayPal, Boston Beer, and PolarityTE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Koninklijke Philips N.V. (NYSE: PHG), PayPal Holdings, Inc. (NASDAQ: PYPL), The...
Oct 01, 2021 08:45 am ET
POLARITYTE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of U
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period").
Sep 30, 2021 12:32 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Sept. 30, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. ("PolarityTE" or "the Company") (NASDAQ: PTE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Sep 30, 2021 10:00 am ET
PTE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies PolarityTE, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pte.
Sep 29, 2021 04:08 pm ET
ROSEN, A RESPECTED AND LEADING FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class...
Sep 29, 2021 12:11 pm ET
POLARITYTE, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of
Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all...
Sep 28, 2021 07:03 pm ET
Sep 28, 2021 09:07 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. (“PolarityTE” or “the Company”) (NASDAQ:
Sep 27, 2021 09:47 pm ET
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of all persons and entities who purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the “Class Period”). Investors have until November 23, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Sep 27, 2021 03:57 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PolarityTE, Inc. (“PolarityTE” or “the Company”) (NASDAQ:
Sep 27, 2021 12:57 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and August 23, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2021.
Sep 27, 2021 10:45 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. (PTE)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PolarityTE, Inc. (“Polarity” or the “Company”) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of those who purchased...
Sep 24, 2021 11:10 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against PolarityTE, Inc. and Certain Officers - PTE
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) and certain of its officers. The class action, filed in the United States District Court for the District of Utah, and docketed under 21-cv-00561, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defe
Sep 07, 2021 08:00 am ET
PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference
PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021 and participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021.
Sep 05, 2021 04:05 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PolarityTE, Inc. - PTE
NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 02, 2021 08:00 am ET
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review Committee
PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis, MD, as Chief Medical Officer.
Aug 31, 2021 10:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PolarityTE, Inc. - PTE
Pomerantz LLP is investigating claims on behalf of investors of PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Aug 24, 2021 09:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PolarityTE, Inc. - PTE
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Aug 24, 2021 08:00 am ET
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021. The FDA provided feedback that certain Chemistry, Manufacturing, and Control (CMC) items need to be addressed prior to proceeding with a pivotal study. As a result, the study proposed in the IND has been plac
Aug 12, 2021 04:00 pm ET
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
Jul 29, 2021 08:00 am ET
PolarityTE to Report Second Quarter Financial Results on August 12, 2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time.
Jul 28, 2021 08:00 am ET
SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial
PolarityTE, Inc. (Nasdaq: PTE) today announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881254). The trial met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) assessed at 4, 6, 8, 10, and 12 weeks. 100 participants were evaluated across 13 sites with 50 participants receiving SkinTE plus SOC and 50 receiving SOC alone. PolarityTE is pleased to announce today the final analysis
Jul 26, 2021 08:00 am ET
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers
PolarityTE, Inc. (Nasdaq: PTE) today announced the submission of an investigational new drug application (IND) to the United States Food and Drug Administration (FDA) seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. SkinTE is PolarityTE’s human cellular and tissue-based product derived from a patient’s own skin.
Jul 16, 2021 10:55 am ET
PolarityTE Issues Statement About Potential Ticker Symbol Confusion
PolarityTE, Inc. (Nasdaq: PTE) is issuing the following statement:
Jul 12, 2021 08:00 am ET
PolarityTE Receives Notice of Allowance for Chinese Patent
PolarityTE, Inc. (Nasdaq: PTE) today announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE’s minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology. Of note, China recently adopted a new law for patent term extension of up to 5 years to compensate for the time taken for review and approval of a new drug or bio
May 13, 2021 04:00 pm ET
PolarityTE Reports First Quarter Results and Provides Business Update
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the first quarter ended March 31, 2021.
May 10, 2021 08:00 am ET
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint
PolarityTE, Inc. (Nasdaq: PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881254) met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) at 12 weeks. 100 patients were evaluated across 13 sites with 50 patients receiving SkinTE plus SOC and 50 patients receiving SOC alone.
May 03, 2021 08:00 am ET
PolarityTE to Report First Quarter Financial Results on May 13, 2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximately 4:00 p.m. Eastern Time.
Mar 30, 2021 07:00 am ET
PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.
Mar 10, 2021 08:00 am ET
PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximately 7:00 a.m. Eastern Time.
Mar 02, 2021 08:00 am ET
PolarityTE to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021.
Feb 10, 2021 08:00 am ET
PolarityTE Provides Corporate Update
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administration (FDA) through submission of an investigational new drug application (IND) and eventual biologics license application (BLA), and protecting our intellectual property.
Feb 03, 2021 04:15 pm ET
PolarityTE Receives Allowance for Additional U.S. Patent
PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 filed on October 19, 2018. This is the Company’s second patent allowance in the United States. The newly allowed claims provide additional protection for methods of making skin-regenerative compositions with the Company’s minimally polarized functional unit (MPFU) technology as well as methods of treatment utilizing the compositions.
Jan 22, 2021 08:45 am ET
PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the agreement by an accredited investor to exercise certain warrants to purchase up to an aggregate of 10,688,043 shares of common stock having an exercise price of $0.624 issued by the company in December 2020. The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-3 (File No. 333-229584). In consideration for the immedi
Jan 21, 2021 08:00 am ET
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 100 subjects in a randomized controlled trial (RCT) evaluating SkinTE® plus standard of care (SOC) versus SOC alone for the treatment of diabetic foot ulcers (DFUs). PolarityTE plans to report topline data via press release and presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2021 to be held May 12-16, 2021, barring any unforeseen scheduling or other disruptions due to COVID-19. Details for the SAWC 2021
Jan 14, 2021 04:05 pm ET
PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today the closing of its previously announced registered direct offering. In the offering the company sold 6,670,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), pre-funded warrants to purchase up to 2,420,910 shares of Common Stock (the “Pre-Funded Warrants”), which have been exercised, and accompanying common warrants to purchase up to 9
Jan 14, 2021 07:30 am ET
Thinking about buying stock in GameStop, Virgin Galactic, Ur-Energy, Polarityte, or Organogenesis Holdings?
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, SPCE, URG, PTE, and ORGO.
Jan 12, 2021 07:00 am ET
PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 9,090,910 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 9,090,910 shares of common stock. Each share of common stock (or pre-funded warra
Jan 11, 2021 08:31 am ET
Thinking about buying stock in Polarityte, Moleculin Biotech, InspireMD, US Well Services, or Resonant?
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, MBRX, NSPR, USWS, and RESN.
Jan 11, 2021 08:00 am ET
PolarityTE Announces Formation of Strategic Review Committee
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed a strategic review committee with a view to enhancing shareholder value. The committee will focus on reviewing operational strategies and practices that advance the regulatory process for SkinTE and future financings, if any, that may be helpful in advancing the Company’s strategies and making recommendations to the Board. The committee also has the authority to review the Company’s potential strategic opportunities and
Jan 08, 2021 07:30 am ET
Thinking about buying stock in Polarityte, Jaguar Health, SRAX, ReneSola, or Marathon Patent Group?
NEW YORK, Jan. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, JAGX, SRAX, SOL, and MARA.
Jan 05, 2021 08:00 am ET
PolarityTE to Present at the H.C. Wainwright Virtual Bioconnect 2021 Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Virtual Bioconnect Conference on January 11, 2021.
Dec 22, 2020 08:00 am ET
PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, announced today that it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor providing for the purchase and sale of 10,688,043 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 10,688,043 shares of common stock. Each share of common stock (or pre-funded war
Nov 30, 2020 08:00 am ET
PolarityTE Receives Allowance for First U.S. Patent
PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is the Company’s first patent allowance in the United States. This patent application, which was originally filed on November 30, 2015, covers methods of making compositions for regenerating functional skin tissue using the Company’s minimally polarized functional unit (MPFU) technology.
Nov 24, 2020 08:00 am ET
PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice
PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials, today announced the dismissal with prejudice of a consolidated class action lawsuit filed in the United States District Court for the District of Utah under the caption In re PolarityTE, Inc. Securities Litigation, Case No. 2:18-cv-00510. The Court’s order was based on the Company’s motion to dismiss filed on June 3, 2019.
Nov 09, 2020 07:00 am ET
PolarityTE Reports Third Quarter 2020 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET.
Nov 02, 2020 08:00 am ET
PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®
PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submitted in August 2020 regarding an indication for SkinTE to treat diabetic foot ulcers (DFUs). FDA’s responses included, among other things, feedback and recommendations on SkinTE manufacturing, preclinical studies, clinical data submitted in the Company’s briefing package, and additional clinical studies to support our IND submission. The Company expects to discuss additional indications in pressure injuries and traumatic wounds wi
Oct 26, 2020 08:00 am ET
PolarityTE to Report Third Quarter 2020 Financial Results on November 9, 2020
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time.
Sep 29, 2020 08:00 am ET
PolarityTE Announces Termination of Shareholder Rights Plan
PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder rights plan, often referred to as a “poison pill,” is effective September 28, 2020. Shareholders are not required, nor do they need, to take any action because of the termination of this shareholder rights plan.
Sep 21, 2020 08:00 am ET
PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds
PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled, “Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds.” The Phase I grant, which totals approximately $245,000, is funded over a six-month period and will support research to apply for a subsequent larger Phase II grant.
Sep 16, 2020 08:00 am ET
SkinTE™ Health Economics—DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure
PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (RCT) evaluating SkinTE for the treatment of diabetic foot ulcers (DFUs), which previously reported statistically significant wound closure rates of 72% for SkinTE plus the standard of care (SOC) vs 32% for the SOC alone (p=0.005).
Sep 14, 2020 08:00 am ET
PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance
PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M.
Sep 10, 2020 08:00 am ET
PolarityTE to Present at H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Virtual Global Healthcare Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Virtual Global Healthcare Conference on September 15, 2020.
Sep 08, 2020 08:00 am ET
PolarityTE Announces Strategic Partnership with Co-Diagnostics to Expand COVID-19 Testing Platform
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that its subsidiary, Arches Research, Inc., has entered into a strategic partnership with Co-Diagnostics, Inc. (Nasdaq: CODX) to expand COVID-19 testing operations.
Aug 06, 2020 07:00 am ET
PolarityTE Reports Second Quarter 2020 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE will host a conference call and webcast today, August 6, 2020 at 8:00 a.m. ET.
Jul 30, 2020 08:00 am ET
PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors
PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors. Dr. Shen brings extensive clinical development, medical, health economics, regulatory, and quality control experience to PolarityTE’s Board of Directors. Dr. Shen spent more than 15 years at Johnson & Johnson, where she was most recently Vice President of Clinical Development and Regulatory Affairs of the Global Surgery Group. Dr. Shen joined Royal Philips over five years ago and currently serves as Senior Vice President, Head of Global Regulatory, Medical, Clinica
Jul 29, 2020 08:00 am ET
PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time.
Jul 24, 2020 09:31 am ET
Thinking about buying stock in Arbutus Biopharma, Polarityte Inc, Milestone Pharmaceuticals, Vonage, or BioNano Genomics?
NEW YORK, July 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, PTE, MIST, VG, and BNGO.
Jul 24, 2020 08:00 am ET
PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE™ Diabetic Foot Ulcer Trial
PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care (SOC) vs SOC alone (NCT03881254). 50 patients were evaluated across 13 sites with 25 patients receiving SkinTE plus SOC and 25 patients receiving only SOC.
Jul 20, 2020 08:00 am ET
PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020
PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial (RCT) entitled “SkinTE™ in the Treatment of Diabetic Foot Wounds” will be featured in a poster presentation at the Symposium on Advanced Wound Care (SAWC) Spring Virtual Conference to be held July 24-26, 2020. This study is a prospective, multi-center RCT designed to collect patient outcome data on SkinTE plus standard of care (SOC) versus SOC alone for the treatment of diabetic foot ulcers (DFUs). The primary endpo
Jun 01, 2020 08:00 am ET
PolarityTE—Two Peer-Reviewed Manuscripts Published on SkinTE
PolarityTE, Inc. (Nasdaq: PTE) reports the recent publication of two peer-reviewed manuscripts involving the application of SkinTE in a pilot study of diabetic foot ulcers and a 15-patient case series evaluating multiple wound types.
May 11, 2020 07:00 am ET
PolarityTE Reports First Quarter 2020 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the first calendar quarter of 2020. PolarityTE will host a conference call and webcast today, May 11, 2020 at 8:00 a.m. ET.
Apr 30, 2020 04:15 pm ET
PolarityTE Provides Update on Corporate Strategy and Regulatory Pathway for SkinTE
PolarityTE, Inc. (Nasdaq: PTE) is providing an update on a change to the strategic focus of the Company and the regulatory pathway for the Company’s SkinTE™ product.
Apr 21, 2020 08:00 am ET
PolarityTE Provides Corporate Update Related to COVID-19 and Announces Preliminary First Quarter Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is providing an update on actions the Company is taking to best position the business and support the Company’s stakeholders in light of the COVID-19 pandemic, and preliminary First Quarter 2020 results.
Apr 13, 2020 08:00 am ET
PolarityTE Announces Data from Head-to-Head Burn Study Demonstrating Graft Take and Wound Closure with SkinTE Treatment
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that data from its Head-to-Head Burn trial was published in the Journal of Burn Care & Research. This abstract was accepted for a podium presentation at the American Burn Association Meeting, which was cancelled due to the COVID-19 pandemic. Eight patients with deep-partial/full thickness burns had a portion of their wounds treated with SkinTE™, an autologous homologous skin construct (AHSC), and the remainder of their burn treated
Apr 08, 2020 08:00 am ET
PolarityTE Announces Conclusion of SEC Investigation
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has received correspondence from the United States Securities and Exchange Commission (“SEC”) advising PolarityTE that the SEC’s investigation relating to a range of securities, financial, personnel, and other matters has concluded. The correspondence states that, based on the information the SEC has received to date, the SEC Staff does not intend to recommend an enforcement action by the SEC against PolarityTE.
Apr 06, 2020 08:00 am ET
PolarityTE Announces the Addition of Audit Executive Chris Nolet to Board of Directors
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Chris Nolet to the Company’s Board of Directors and Chair of the Audit Committee. Mr. Nolet brings extensive audit and business experience with nearly forty years in the profession, most recently as the West Region Life Sciences Industry Leader and Partner at EY. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group.
Apr 01, 2020 08:00 am ET
PolarityTE Announces Appointment of David Seaburg as CEO and Restructuring of Executive Team
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that the Company’s Board of Directors has restructured the executive team to more appropriately align with traditional management structures, dissolving the Office of the Chief Executive, which had been in place since August 2019. David Seaburg has been appointed Chief Executive Officer of PolarityTE. Richard Hague has assumed the role of President, while maintaining his responsibilities as Chief Operating Officer. Paul Mann, who previousl
Mar 12, 2020 07:00 am ET
PolarityTE Reports Fiscal Year 2019 Financial Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported results for calendar fourth quarter and year ended December 31, 2019. PolarityTE will host a conference call and webcast with Q&A today, Thursday, March 12, 2020 at 8:00 a.m. Eastern Time. Please see details below.
Mar 05, 2020 08:00 am ET
PolarityTE to Attend the Oppenheimer 30th Annual Healthcare Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that it will attend the Oppenheimer 30th Annual Healthcare Conference held on March 17-18, 2020 in New York, NY.
Mar 03, 2020 08:00 am ET
PolarityTE to Report Fiscal Year 2019 Financial Results on March 12, 2020
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report financial results for the year ended December 31, 2019, by press release on Thursday, March 12, 2020 at approximately 7:00 a.m. Eastern Time.
Feb 18, 2020 06:38 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of PolarityTE, comScore, AMC, and Conagra Brands and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of PolarityTE, Inc. (NASDAQ: PTE), comScore, Inc. (NASDAQ: SCOR), AMC Entertainment Holdings, Inc. (NYSE: AMC), and Conagra...
Feb 12, 2020 09:00 am ET
PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the pricing of an underwritten public offering of approximately 10,638,298 shares of its common stock and warrants to purchase up to 10,638,298 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $2.35 per share and warrant, for a gross offering size of $25.0 million, not including any future proceeds from the exercise of
Feb 11, 2020 04:01 pm ET
PolarityTE Announces Public Offering of Common Stock and Warrants
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.
Dec 18, 2019 08:00 am ET
PolarityTE to Participate in Corporate Access Event in San Francisco, January 13-15, 2020
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that senior management will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place at the Sir Francis Drake Hotel in San Francisco, January 13-15, 2020.
Dec 10, 2019 08:00 am ET
PolarityTE Builds Patent Portfolio with New International Patent Grants
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that the company has recently been granted a patent in New Zealand and has received approvals for patent applications in the United Kingdom and Australia. The grant of PolarityTE’s Canadian patent was
Dec 05, 2019 08:00 am ET
PolarityTE Announces Equity Purchase Agreement for up to $25 Million with Keystone Capital Partners
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has entered into a $25.0 million equity purchase agreement (the “Agreement”) with Keystone Capital Partners, LLC (“Keystone”), a New York-based institutional investor.
Nov 27, 2019 08:00 am ET
PolarityTE to Attend Evercore ISI 2nd Annual HealthCONx Conference and Piper Jaffray 31st Annual Healthcare Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will attend the Evercore ISI HealthCONx Conference on Tuesday, December 3, 2019 in Boston and the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York, NY.
Nov 12, 2019 04:05 pm ET
PolarityTE Reports Third Calendar Quarter 2019 Results
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2019. PolarityTE will host a conference call and webcast today, November 12, 2019 at 4:30pm ET. Please see details below.
Nov 07, 2019 04:01 pm ET
PolarityTE Adopts Short-Term Shareholder Rights Plan
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that its Board of Directors approved a short-term shareholder rights agreement (“the Rights Agreement”) following an evaluation by the Shareholder Rights Committee established by the Board in August 2019.
Oct 24, 2019 08:00 am ET
PolarityTE to Report Calendar Third Quarter Financial Results on November 12, 2019
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report calendar third quarter 2019 financial results by press release on Tuesday, November 12, 2019 at approximately 4:00 p.m. Eastern Time.
Oct 14, 2019 08:00 am ET
PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined the impact of SkinTE™, a novel human cellular and tissue-based product derived from a patient's own skin, in closing venous stasis leg ulcers (VLUs) following failure of conventional treatments. The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulc
Oct 06, 2019 10:00 am ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of National General Holdings, Natural Health Trends, Omnicell, and Polarity TE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of National General Holdings Corp. (NASDAQ: NGHC), Natural Health Trends Corp. (NASDAQ: NHTC), Omnicell, Inc. (NASDAQ: OMCL), and PolarityTE, Inc. (NASDAQ: PTE) on behalf of...
Oct 03, 2019 08:00 am ET
SkinTE Data to be Presented at the 19th Annual Diabetic Foot Global Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that two abstracts demonstrating the impact of the Company’s SkinTE™ product in treating diabetes-related wounds were accepted for poster presentations at the 2019 Diabetic Foot Global Conference (DFCon), an international, interdisciplinary diabetic foot conference hosted by the Keck School of Medicine of University of Southern California in collaboration with Baylor College of Medicine and University of California San Francisco fro
Sep 26, 2019 08:00 am ET
PolarityTE Selected to Present at 2019 Cell & Gene Meeting on the Mesa
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that Nikolai Sopko, MD, PhD, Chief Scientific Officer of PolarityTE, was selected to present at the annual Cell & Gene Meeting on the Mesa, which will be held from October 2-4, 2019 in Carlsbad, California. Dr. Sopko will discuss the Company’s R&D pipeline and highlight the progress made thus far with the Company’s first clinically available product, SkinTE™, an autologous, homologous human cellular and tissue-based product designed
Sep 23, 2019 08:00 am ET
PolarityTE Announces Positive Data Showing SkinTE Regenerated Full-Thickness Skin in Difficult-to-Treat Wounds
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from a study showing positive impact of the Company’s SkinTE™ skin regeneration product on a broad range of cases, demonstrating progressive wound closure including coverage of exposed underlying structures such as bone and tendon. Highlights of these findings were reported in a podium presentation at the American Society of Plastic Surgeons’ (ASPS) 2019 scientific meeting, Plastic Surgery The Meeting, held in San Diego, Se
Sep 18, 2019 08:00 am ET
PolarityTE to Attend the 2019 Cantor Global Healthcare Conference
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 in New York, NY.
Sep 16, 2019 08:00 am ET
SkinTE Data Including Final Pilot Study Data Readout to be Presented at the Symposium on Advanced Wound Care Fall Meeting
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that four abstracts regarding the Company’s SkinTE™ product were accepted for poster presentations at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Las Vegas, which will be held from October 12-14, 2019. Notably, the final data readout from the Company’s pilot trial evaluating SkinTE for the treatment of venous stasis leg ulcers will be presented at the conference and was named the highest scoring poster abstract in th
Sep 09, 2019 08:00 am ET
SkinTE Data to be Presented at the American Society of Plastic Surgeons 88th Annual Scientific Meeting
SALT LAKE CITY, Sept. 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that an abstract with data from 15 patient cases where the Company's SkinTE™ product was used to treat a variety of wounds was accepted for a podium presentation at the American Society of Plastic Surgeons' scientific meeting, Plastic Surgery The Meeting, which will be held in San Diego from September 20-23, 2019.
Sep 04, 2019 08:00 am ET
PolarityTE Appoints Peter Cohen as Chairman of the Board
SALT LAKE CITY, Sept. 4, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board.
Aug 28, 2019 08:00 am ET
PolarityTE to Attend H.C. Wainwright 21st Annual Healthcare Conference and Morgan Stanley 17th Annual Global Healthcare Conference
SALT LAKE CITY, Aug. 28, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 in New York, NY. PolarityTE also announced that it will attend and meet with investors during the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York, NY.
Aug 20, 2019 12:55 pm ET
PolarityTE Granted Canadian Patent
SALT LAKE CITY, Aug. 20, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that the Canadian Intellectual Property Office has granted Patent No. 2 969 707 entitled "Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5, And LGR6 Expressing Epithelial Stem Cells."
Aug 16, 2019 08:00 am ET
PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL.
Aug 08, 2019 07:00 am ET
PolarityTE Reports Second Calendar Quarter 2019 Results
SALT LAKE CITY, Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2019. PolarityTE will host a conference call and webcast today, August 8, 2019 at 8:00am ET. Please see details below.
Jul 25, 2019 08:00 am ET
PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time.
May 21, 2019 08:00 am ET
Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference
SALT LAKE CITY, May 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that final data from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs), will be presented at the American Diabetes Association's 79th Scientific Sessions conference at the Moscone Center in San Francisco, California. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional
May 10, 2019 07:30 am ET
PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE
SALT LAKE CITY, May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today data from two pilot studies on the use of its SkinTE™ product both showing successful closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE.
May 10, 2019 07:16 am ET
PolarityTE Reports First Calendar Quarter 2019 Results
SALT LAKE CITY, May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial results for the first calendar quarter of 2019. PolarityTE will host a conference call and webcast today, May 10, 2019 at 8:00am ET. Please see details below.
May 01, 2019 08:00 am ET
PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019
SALT LAKE CITY, May 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar first quarter 2019 financial results by press release on May 10, 2019 at approximately 7:00 a.m. Eastern Time.
Apr 24, 2019 08:00 am ET
SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting
SALT LAKE CITY, April 24, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that new clinical data on the use of its SkinTE™ product will be presented at the Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society meeting in San Antonio, TX from May 7 – 11, 2019. In addition, PolarityTE will host a booth and an interactive event featuring patients treated with SkinTE and a presentation from Dr. Gerhard S. Mundinger, MD, Division of Plastic Surgery, Louisiana
Apr 10, 2019 09:30 am ET
PolarityTE Announces Pricing of Public Offering of Common Stock
SALT LAKE CITY, April 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today the pricing of an underwritten public offering of approximately $27.5 million of shares of its common stock. In addition, PolarityTE has granted the underwriter a 30-day option to purchase up to $4,125,000 of additional shares of its common sto
Apr 09, 2019 04:01 pm ET
PolarityTE Announces Public Offering of Common Stock
SALT LAKE CITY, April 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, PolarityTE intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock
Apr 02, 2019 04:34 pm ET
Apr 01, 2019 08:00 am ET
PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds
SALT LAKE CITY, April 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that patient enrollment has begun for two new randomized controlled trials evaluating SkinTE™ for the treatment of chronic wounds, specifically diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). SkinTE is commercially available through a regional market release and is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, func
Mar 29, 2019 08:00 am ET
PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer
SALT LAKE CITY, March 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that Richard Hague will join as the Company's Chief Operating Officer on April 8, 2019. Mr. Hague brings to PolarityTE experience in many aspects of corporate development and operations from his more than 30-year career in the biotechnology industry, including launching a variety of autologous cell and tissue therapies. Current COO Ned Swanson, MD, will continue on as PolarityTE's Chief Translation
Mar 27, 2019 08:00 am ET
Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference
SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two clinical outcomes abstracts on SkinTE™ for the treatment of diabetic foot ulcers (DFUs) will be presented at the Diabetic Limb Salvage (DLS) Conference in Washington, DC being held on April 4-6, 2019. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacem
Mar 21, 2019 08:00 am ET
PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting
SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today it will host a symposium at the American Burn Association (ABA) 51st Annual Meeting featuring a burn survivor who will share her story after being treated with the Company's SkinTE™ product. Additionally, two abstracts on the clinical use of SkinTE will be presented during the conference.
Mar 19, 2019 05:00 pm ET
PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference
SALT LAKE CITY, March 19, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that it will attend and present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 in New York City. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Mar 19, 2019 02:15 pm ET
RM LAW Announces Investigation of PolarityTE, Inc.
BERWYN, Pa., March 19, 2019 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of PolarityTE, Inc. (NASDAQ: PTE) ("PolarityTE" or the "Company") investors concerning the Company and its officers' possible violations of federal securities laws.
Mar 19, 2019 01:06 pm ET
Federman & Sherwood Investigates PolarityTE, Inc. for Possible Violations of Federal Securities Laws
The law firm of Federman & Sherwood has initiated an investigation into
PolarityTE, Inc. (NASDAQ: PTE) with respect to possible violations of
federal securities laws.
Mar 19, 2019 10:47 am ET
PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation of PolarityTE, Inc. - PTE
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, Inc. (“PolarityTE” or the “Company”) (NASDAQ: PTE) resulting from allegations that...
Mar 18, 2019 07:56 pm ET
Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. (PTE) on Behalf of Stockholders and Encourages PTE Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE). Our investigation concerns whether PolarityTE has violated the federal securities laws and/or engaged in other unlawful business practices. Click...
Mar 18, 2019 05:40 pm ET
PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE
NEW YORK, March 18, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, Inc. ("PolarityTE" or the "Company") (NASDAQ: PTE) resulting from allegations that PolarityTE and/or its executives may have issued materially misleading business information to the investing public.
Mar 18, 2019 07:00 am ET
PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018
SALT LAKE CITY, March 18, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today reported financial results for the two-month transition period that ended December 31, 2018. As previously announced, PolarityTE is transitioning from an October 31 fiscal year end to a December 31 fiscal year end. For additional details,
Mar 13, 2019 08:45 am ET
PolarityTE to Attend Medlab Asia Pacific and Asia Health 2019 Conferences
SALT LAKE CITY, March 13, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that it will attend the Medlab Asia Pacific and Asia Health 2019 conferences in Singapore from March 26-28, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Mar 06, 2019 03:01 pm ET
PolarityTE to Present at the 39th Annual Cowen Healthcare Conference and at the 13th Annual Canaccord Genuity Musculoskeletal Conference
SALT LAKE CITY, March 6, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that it will attend and present at the Cowen 39th Annual Healthcare Conference on March 11, 2019 in Boston, MA and the 13th Annual Canaccord Genuity Musculoskeletal Conference on March 12, 2019 in Las Vegas, NV. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Mar 05, 2019 07:00 am ET
Congressional Health Care Innovation Showcase to Feature PolarityTE
SALT LAKE CITY, March 5, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that its platform technology will be featured at the U.S. House of Representatives' Health Care Innovation Showcase in Washington, DC on March 7, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Feb 27, 2019 07:00 am ET
PolarityTE Presents Platform Technology at Department of Defense Pacific Operational Science and Technology (POST) Conference
SALT LAKE CITY, Feb. 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) announced today that its platform technology will be featured at the 2019 Pacific Operational Science and Technology (POST) Conference, co-sponsored by the United States Indo-Pacific Command and TechConnect, held March 4-8, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Feb 01, 2019 07:00 am ET
Boswick Burn and Wound Symposium: New Data to be Presented on Preclinical and Clinical Use of SkinTE™
SALT LAKE CITY, Feb. 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that new data on the preclinical and clinical use of its SkinTE™ product, a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement, will be presented at the 41st Annual Boswick Burn and Wound Symposium, February 2-7, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of r
Jan 29, 2019 03:15 pm ET
PolarityTE Names Board Member David Seaburg as President of Corporate Development
SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that David Seaburg will join the Company in the newly-created role of President of Corporate Development. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Jan 23, 2019 07:00 am ET
World Stem Cell Summit: PolarityTE to Present Abstract on Regenerative Platform Technology
SALT LAKE CITY, Jan. 23, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that it will present an abstract highlighting the PolarityTE platform technology at the Regenerative Medicine Foundation World Stem Cell Summit in Miami, Florida on January 24, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
Jan 14, 2019 06:00 am ET
PolarityTE Reports Fourth Quarter and Fiscal Year 2018 Results
SALT LAKE CITY, Jan. 14, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today reported financial results for the fourth quarter and fiscal year ended October 31, 2018, and full-year operational milestones. PolarityTE will host a conference call and webcast today, January 14, 2019 at 8:00am ET. Please see details below.
Jan 07, 2019 07:00 am ET
PolarityTE Expands Contract Services Business with Addition of Jon Burrows
SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the appointment of Jon Burrows, PhD as President of Contract Services and Senior Vice President of Corporate Development. Dr. Burrows will oversee the market expansion of the Company's contract research organization (CRO) services, including that
Jan 03, 2019 07:00 am ET
PolarityTE to Report Fiscal Fourth Quarter Financial Results on January 14, 2019
SALT LAKE CITY, Jan. 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced that it will report its fiscal fourth quarter 2018 financial results by press release on January 14, 2019 at approximately 7:00 a.m. Eastern Time.
Dec 28, 2018 07:00 am ET
PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration
SALT LAKE CITY, Dec. 28, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced that it registered OsteoTE™ with the U.S. Food and Drug Administration (FDA) pursuant to applicable regulations governing human cells, tissues and cellular and tissue-based products (HCT/Ps).
Dec 27, 2018 07:00 am ET
PolarityTE to Participate in Corporate Access Event in San Francisco, January 7-9, 2019
SALT LAKE CITY, Dec. 27, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced that senior management will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 7-9, 2019.
Dec 19, 2018 07:00 am ET
PolarityTE and University Hospitals Cleveland Medical Center Announce System-Wide Approval of SkinTE™
SALT LAKE CITY and CLEVELAND, Dec. 19, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products using a patient's own tissue, and the University Hospitals Cleveland Medical Center jointly announced today that SkinTE™ is now available for use throughout the UH network of healthcare facilities. SkinTE is the first commercially-available autologous, homologous product that regenerates full-thickness skin that is fully-functional, and
Dec 11, 2018 07:00 am ET
PolarityTE Announces Former FDA Official and Johnson & Johnson Executive Minnie Baylor-Henry Joins Board of Directors
SALT LAKE CITY, Dec. 11, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the addition of Minnie Baylor-Henry to the Company's Board of Directors. Ms. Baylor-Henry is a regulatory affairs leader who served for nearly a decade at the U.S. Food and Drug Administration (FDA) before spending most of her career at Johnson
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.